DOCSLIB.ORG

Inherited Enzyme Defects: a Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inherited Enzyme Defects: a Review J Clin Pathol: first published as 10.1136/jcp.16.4.293 on 1 July 1963. Downloaded from J. clin. Path. (1963), 16, 293 Inherited enzyme defects: a review T. HARGREAVES' From the Department of Chemical Pathology, St. George's Hospital Medical School, Hyde Park Corner, London, S. W.I Sir Archibald Garrod in 1909 pointed out that four The consequences of a genetic change and an diseases, albinism, alkaptonuria. cystinuria, and alteration in the quality or quantity of a protein will pentosuria, were present from birth, lasted through- depend on the role normally subserved by that out life without worsening or improvement, and protein; in the cases that we are considering this is were present in other members of the family (Garrod, derangement of enzymatic function. The derange- 1909). These diseases were described as 'inborn errors ments that can occur include a blocked metabolic of metabolism'. The original four diseases have sequence. In the reaction A---* B-- C--# D, if been expanded to over 50 and the actual site of the C--# D is blocked then a clinical disorder may biochemical abnormality has been elucidated in many result from a failure to produce D, e.g., hypo- of them. In this review we shall consider those glycaemia due to an inability to form glucose from diseases which are either known or thought to be glucose-6-phosphate in von Gierke's disease. The due to single enzyme defects. We have not con- precursor C may accumulate; for example, bilirubin sidered those diseases that are thought to be due to accumulates in the absence of glucuronyl transferase. renal tubular or intestinal abnormalities, for The remote precursers A and B may accumulate, for example, cystinuria. It is not yet known whether example, glycogen in von Gierke's disease. The block this type of disease is due to a specific enzyme between C and D may result in an increased utiliza- defect. tion of normally minor pathways, for example, in The fundamental discovery of Mendel (1901) con- phenylketonuria. The application of these metabolic cerning the inheritance of plant characters had just cycles will be reviewed in each section. been resurrected and given prominence at the time The subject has been covered generally in recent http://jcp.bmj.com/ when Garrod was most active. The transmission of reviews, for example, that of Stanbury, Wyngaarden, a single character as a governing agent for a single and Fredrickson (1960). enzyme and accordingly, as one step in intermediary metabolism, seems implicit in Garrod's writings but DISTURBANCES IN AMINO-ACID METABOLISM is never stated as such. The concept attained clear definition in the 'one gene-one enzyme' principle Recent advances in the past few years in the under- first clearly stated by Beadle (1945). The formulation standing of the biochemistry of the amino-acids on September 25, 2021 by guest. Protected copyright. emerged gradually from studies of eye colour in the coupled with the use of amino-acid chromatography fruit fly Drosophila and received extensive support in urine has helped to elucidate problems in the from work done on induced mutants of Neurospora disturbance of amino-acid metabolism and to crassa. The concept has been expressed as: 1 All demonstrate new cases of disturbed amino-acid biochemical processes in all organisms are under metabolism. genic control. 2 These biochemical processes are resolvable into series of individual stepwise reactions. 3 Each biochemical reaction is under the ultimate PHENYLKETONURIA In 1934 F0oling described 10 control of a different gene. 4 Mutation of a single patients, some of them siblings, who excreted phenyl gene results only in an alteration in the ability of the pyruvic acid and were mentally deficient. Jervis cell to carry out a single primary chemical reaction. (1953) demonstrated that phenylalanine hydroxylase It is now realized that the one gene-one enzyme of the liver was inactive in these patients. The concept does not require a one enzyme-one gene condition is inherited through a single autosomal corollary, and that the 'gene' is being replaced by recessive gene. It is required that both parents of a progressively smaller units of ultimate genetic patient have the defective form of one of the two control. genes controlling phenylalanine hydroxylase; an apparent reduction of phenylalanine hydroxylase IB.M.A. research scholar can be detected in the parents. On the average one 293 J Clin Pathol: first published as 10.1136/jcp.16.4.293 on 1 July 1963. Downloaded from 294 T. Hargreaves Albinism Phenylalanine I , Phenyl- Phenylalanine \\-CH.CH COOH Tyrosinase ketonuria hydroxylase -\NH Tyrosine 3,4 Dihydroxyphenylalanine 3,4 Dopaquinone--oMelanin HO/ CHCHCOOH HO NH. HO- -CH2.CH COOH O= -CH2CH2COC ?Tyrosinosis Tyrosine transam nase NH, NH., p-Hydroxyphenylpyruvic acid - 4 p-Hydroxyphenyllactic acid p hydroxy- - \ \-CHi.,CH COOH Tyrosinosis phenylpyruvic HO/ CH2C COOH HO-/ (Medes) acid oxidase \. O.-Ii0 OH Homr entisic acid Alkaptonuria Homogentisic acid oxidase HO/_-\\HO I\CH ,COOH Maleylacetoacetic acid FIG. 1. Metabolic blocks in thle oxida(tioni of I plhenylalanine ani(l tYrosine. Fumarylacetoacetic acid http://jcp.bmj.com/ Fumaric acid t- acetoacetic acid out of four offspring from two heterozygous parents Mitoma, Auld, and Udenfriend (1957) showed that has both genes defective, and in these offspring two protein fractions are involved in this reaction, a phenylketonuria results. The disability is first labile fraction I found in liver and a more stable manifest several weeks after birth, initially by fraction II found in kidney and heart. The system on September 25, 2021 by guest. Protected copyright. elevation of the plasma phenylalanine level and by required N.A.D. or N.A.D.P. and iron together with the excretion of phenylpyruvic acid. After six an unknown but necessary coenzyme which can be months, retardation of mental development is replaced by tetrahydrofolic acid. Fraction I is deficient apparent. Many of the children have blond hair, in phenylketonuria. blue eyes and fair skin, and a few show a tendency The deficiency of phenylalanine hydroxylase to develop dermatitis or eczema. The majority of causes an excessive accumulation of phenylalanine patients have an I.Q. of 30 or less. in the blood and cerebrospinal fluid. The excessive Pathogenesis Phenylalanine is converted to tyro- phenylalanine is converted by its transaminase to sine by the enzyme system 'phenylalanine hydrox- phenylpyruvic acid, and this in turn is converted to ylase' in the liver alone; the reaction can be repre- phenyllactic acid, phenylacetic acid, and phenyl- sented as acetyl glutamine, which are excreted in the urine. o-Hydroxyphenylacetic acid, m-hydroxyphenylacetic L-phenylalanine.02±+N.A.D.P.H.-1 +H+--+- and ++ H20- acid, and indole products derived from tyrosine L-tyrosine+-N.A.D.P. tryptophan are also found in the urine of such 'The following abbreviations are used The excessive phenylalanine inhibits the A.T.P. Adenosine Triphosphate patients. N.A.D. Nicotinamide-adenine dinucleotide normal pathways of tyrosine metabolism, there is a N.A.D.P. Nicotinamide-adenine dinucleotide phosphate decreased formation of melanine accounting for U.D.P.G.A. Uridine diphosphate glucuronic acid U.D.P. Uridine 5'-pyrophosphate the blond hair and blue eyes; plasma adrenaline J Clin Pathol: first published as 10.1136/jcp.16.4.293 on 1 July 1963. Downloaded from Inherited enzyme defects: a review 295 levels are low in phenylketonurics. The excessive bolism of phenylalanine and tyrosine, cannot be phenylalanine or one of its products possibly metabolized; it accumulates and is excreted in the damages the central nervous system; the patients are urine. If the urine is allowed to stand it becomes mentally retarded and have epileptic seizures and dark and this sign leads to early recognition of the abnormal electroencephalograms. disease. Boedeker (1859) first diagnosed the disease The condition can be diagnosed by the presence with certainty and used the property of avid oxygen of phenylpyruvic acid in the urine and an increase uptake to give the substance a name 'alkapton'. of phenylalanine in the plasma. Heterozygotes can Garrod in 1909 wrote of the probable defect: 'We be detected by phenylalanine tolerance tests. The may further conceive that the splitting of the benzene homozygous condition can be ameliorated by giving ring in normal metabolism is the work of a special the infants a diet low in phenylalanine, which has no enzyme, that in congenital alkaptonuria this enzyme effect on older children, demonstrating that early is wanting, whilst in disease its working may be diagnosis of the disease is essential. partially or even completely inhibited'. The con- dition is compatible with long life. Except for the TYROSINOSiS This is a very rare inborn error of dark-coloured urine there are no clinical manifesta- metabolism described by Medes (1932). Her patient tions until the second or third decade when was a male Russian Jew who excreted large quantities ochronosis begins to appear. Black pigments are of p-hydroxyphenylpyruvic acid and other tyrosine deposited in various parts of the body, and eventually metabolites but had no clinical symptoms. Medes, the patients develop deforming arthritis in middle Berglund, and Lohmann (1927) found an excess of age. p-hydroxyphenylpyruvic acid in the urine of a Garrod (1902) first described the inheritance of patient with myasthenia gravis, and Felix, Leonhardi. alkaptonuria and presented evidence that the con- and Glasenapp (1951) made similar observations on dition was congenital and familial. He suggested two patients with liver disease. The amount of that it was inherited as a single recessive gene. p-hydroxyphenylpyruvic acid excreted was consider- A study of the cases reported since that time has ably less than 50 mg. per day and it is probable that supported the view that the defect is due to a single these cases are of a different type of metabolic recessive autosomal gene, and gains further support abnormality from the case described by Medes.
Load more

Recommended publications
  • Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations
    REVIEW OFFICIAL JOURNAL Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations www.hgvs.org Arunkanth Ankala,1∗ † Parag M. Tamhankar,2 † C. Alexander Valencia,3,4 Krishna K. Rayam,5 Manisha M. Kumar,5 and Madhuri R. Hegde1 1Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia; 2ICMR Genetic Research Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India; 3Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 4Department of Pediatrics, University of Cincinnati Medical School, Cincinnati, Ohio; 5Department of Biosciences, CMR Institute of Management Studies, Bangalore, Karnataka, India Communicated by Arupa Ganguly Received 24 October 2013; accepted revised manuscript 16 September 2014. Published online 27 November 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22704 that include a lack of widespread awareness about genetic disorders in the general population and the scarcity of specialized medical ABSTRACT: South Asian Indians represent a sixth of the world’s population and are a racially, geographically, and professionals and affordable genetic tests. Seeking a molecular di- genetically diverse people. Their unique anthropological agnosis and understanding the risk estimates are critical to making structure, prevailing caste system, and ancient religious sound reproductive choices, especially in families with an affected practices have all impacted the genetic composition of most individual. Adding to this adversity is the absence of a properly func- of the current-day Indian population. With the evolving tioning social health care system and insufficient encouragement socio-religious and economic activities of the subsects and of individual health insurance by the government.
    [Show full text]
  • Melanocytes and Their Diseases
    Downloaded from http://perspectivesinmedicine.cshlp.org/ on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Melanocytes and Their Diseases Yuji Yamaguchi1 and Vincent J. Hearing2 1Medical, AbbVie GK, Mita, Tokyo 108-6302, Japan 2Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 Correspondence: [email protected] Human melanocytes are distributed not only in the epidermis and in hair follicles but also in mucosa, cochlea (ear), iris (eye), and mesencephalon (brain) among other tissues. Melano- cytes, which are derived from the neural crest, are unique in that they produce eu-/pheo- melanin pigments in unique membrane-bound organelles termed melanosomes, which can be divided into four stages depending on their degree of maturation. Pigmentation production is determined by three distinct elements: enzymes involved in melanin synthesis, proteins required for melanosome structure, and proteins required for their trafficking and distribution. Many genes are involved in regulating pigmentation at various levels, and mutations in many of them cause pigmentary disorders, which can be classified into three types: hyperpigmen- tation (including melasma), hypopigmentation (including oculocutaneous albinism [OCA]), and mixed hyper-/hypopigmentation (including dyschromatosis symmetrica hereditaria). We briefly review vitiligo as a representative of an acquired hypopigmentation disorder. igments that determine human skin colors somes can be divided into four stages depend- Pinclude melanin, hemoglobin (red), hemo- ing on their degree of maturation. Early mela- siderin (brown), carotene (yellow), and bilin nosomes, especially stage I melanosomes, are (yellow). Among those, melanins play key roles similar to lysosomes whereas late melanosomes in determining human skin (and hair) pigmen- contain a structured matrix and highly dense tation.
    [Show full text]
  • Leading Article the Molecular and Genetic Base of Congenital Transport
    Gut 2000;46:585–587 585 Gut: first published as 10.1136/gut.46.5.585 on 1 May 2000. Downloaded from Leading article The molecular and genetic base of congenital transport defects In the past 10 years, several monogenetic abnormalities Given the size of SGLT1 mRNA (2.3 kb), the gene is large, have been identified in families with congenital intestinal with 15 exons, and the introns range between 3 and 2.2 kb. transport defects. Wright and colleagues12 described the A single base change was identified in the entire coding first, which concerns congenital glucose and galactose region of one child, a finding that was confirmed in the malabsorption. Subsequently, altered genes were identified other aZicted sister. This was a homozygous guanine to in partial or total loss of nutrient absorption, including adenine base change at position 92. The patient’s parents cystinuria, lysinuric protein intolerance, Menkes’ disease were heterozygotes for this mutation. In addition, it was (copper malabsorption), bile salt malabsorption, certain found that the 92 mutation was associated with inhibition forms of lipid malabsorption, and congenital chloride diar- of sugar transport by the protein. Since the first familial rhoea. Altered genes may also result in decreased secretion study, genomic DNA has been screened in 31 symptomatic (for chloride in cystic fibrosis) or increased absorption (for GGM patients in 27 kindred from diVerent parts of the sodium in Liddle’s syndrome or copper in Wilson’s world. In all 33 cases the mutation produced truncated or disease)—for general review see Scriver and colleagues,3 mutant proteins.
    [Show full text]
  • Joosten, Han M.L.J.; Herst, Patricia M.; Drift, Chris Van Der
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Groningen University of Groningen Characterization of Glutamine-Requiring Mutants of Pseudomonas aeruginosa Janssen, Dick B.; Joosten, Han M.L.J.; Herst, Patricia M.; Drift, Chris van der Published in: Archives of Microbiology IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1982 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Janssen, D. B., Joosten, H. M. L. J., Herst, P. M., & Drift, C. V. D. (1982). Characterization of Glutamine- Requiring Mutants of Pseudomonas aeruginosa. Archives of Microbiology, 131(4). Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 12-11-2019 JOURNAL OF BACTERIOLOGY, Sept. 1982, p. 1176-1183 Vol. 151, No.
    [Show full text]
  • University of Cincinnati
    UNIVERSITY OF CINCINNATI Date: August 29, 2006 I, Smita Chawla hereby submit this work as a part of the requirements of the degree of: Doctor of Philosophy (Ph. D.) in: Pharmaceutical Sciences It is entitled: Effect of deoxyArbutin and it’s second-generation derivatives on melanocyte viability and function. on Human Nail Permeabili ty . This work and its defense approved by: R. Randall Wickett, Ph.D., Chair Raymond E. Boissy, Ph.D. William Cacini, Ph.D. Prashiela Manga, Ph.D. Marty O. Visscher, Ph.D. EFFECT OF DEOXYARBUTIN AND ITS SECOND-GENERATION DERIVATIVES ON MELANOCYTE VIABILITY AND FUNCTION A dissertation submitted to the Division of Research and Advanced Studies of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in the Division of Pharmaceutical Sciences of the College of Pharmacy 2006 by Smita Chawla B.S. in Pharmaceutical Sciences Mumbai University, Mumbai, India, 2001 Committee Chair: Randall Wickett, Ph.D. ABSTRACT Therapeutic treatment of skin pigmentary disorders such as melasma, solar lentigines, and post inflammatory hyperpigmentation has been challenging and seldom completely successful. The majority of these therapies target tyrosinase, a key enzyme required for pigment synthesis. The lack of success is due to the less than desired efficacy and safety of tyrosinase inhibitors marketed as skin lightening agents (i.e. hydroquinone, kojic acid and arbutin). We propose that the tyrosinase inhibitor deoxyArbutin (dA) and second-generation derivatives of dA, deoxyFuran, thio-dA, and fluoro-dA, have the potential to be effective inhibitors of skin melanization. In this study, we have analyzed the modulating effects of dA and its derivatives on melanocyte function and viability.
    [Show full text]
  • Oxalate Loading Test: a Screening Test for Steatorrhoea
    Gut: first published as 10.1136/gut.20.12.1089 on 1 December 1979. Downloaded from Gut, 1979, 20, 1089-1094 Oxalate loading test: a screening test for steatorrhoea D. S. RAMPTON', G. P. KASIDAS, G. ALAN ROSE, AND MARTIN SARNER2 From University College Hospital, London, St. Peter's Hospitals and Institute of Urology, London SUMMARY To investigate the possibility of measuring urinary oxalate output instead of faecal fat excretion as an outpatient screening test for steatorrhoea, we determined 24 hour urinary oxalate and five day faecal fat excretion before and during an oral load of sodium oxalate 600 mg daily (oxalate 4-44 mmol), in 32 patients with suspected malabsorption on a diet containing oxalate 30 mg (0-33 mmol), fat 50 g (180 mmol), and calcium 1 g (25 mmol). Nineteen patients proved to have steatorrhoea (mean faecal fat 62 mmol/24 h, range 19-186 mmol) of varying aetiologies. On the diet alone, urinary oxalate was raised in only nine of these patients (mean 0 25 mmol/24 h, range 0-08-059 mmol) (normal <0 20). By contrast, when the diet was supplemented with oral sodium oxalate, all 19 patients with steatorrhoea had hyperoxaluria (mean 0-91 mmol/24 h, range 046- 1P44 mmol) (normal <0-44). There was a significant positive linear relationship between urinary oxalate and faecal fat when the 32 patients were on the high oxalate intake (r=0*73, P <0.001), but not when they were on the low oxalate intake. Mean percentage absorption of orally administered oxalate was 58+09% (±1 SD) in normal subjects and 14-7+6-0% (P <0.002) in patients with steatorrhoea.
    [Show full text]
  • The Janus-Like Role of Proline Metabolism in Cancer Lynsey Burke1,Innaguterman1, Raquel Palacios Gallego1, Robert G
    Burke et al. Cell Death Discovery (2020) 6:104 https://doi.org/10.1038/s41420-020-00341-8 Cell Death Discovery REVIEW ARTICLE Open Access The Janus-like role of proline metabolism in cancer Lynsey Burke1,InnaGuterman1, Raquel Palacios Gallego1, Robert G. Britton1, Daniel Burschowsky2, Cristina Tufarelli1 and Alessandro Rufini1 Abstract The metabolism of the non-essential amino acid L-proline is emerging as a key pathway in the metabolic rewiring that sustains cancer cells proliferation, survival and metastatic spread. Pyrroline-5-carboxylate reductase (PYCR) and proline dehydrogenase (PRODH) enzymes, which catalyze the last step in proline biosynthesis and the first step of its catabolism, respectively, have been extensively associated with the progression of several malignancies, and have been exposed as potential targets for anticancer drug development. As investigations into the links between proline metabolism and cancer accumulate, the complexity, and sometimes contradictory nature of this interaction emerge. It is clear that the role of proline metabolism enzymes in cancer depends on tumor type, with different cancers and cancer-related phenotypes displaying different dependencies on these enzymes. Unexpectedly, the outcome of rewiring proline metabolism also differs between conditions of nutrient and oxygen limitation. Here, we provide a comprehensive review of proline metabolism in cancer; we collate the experimental evidence that links proline metabolism with the different aspects of cancer progression and critically discuss the potential mechanisms involved. ● How is the rewiring of proline metabolism regulated Facts depending on cancer type and cancer subtype? 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; ● Is it possible to develop successful pharmacological ● Proline metabolism is widely rewired during cancer inhibitor of proline metabolism enzymes for development.
    [Show full text]
  • Amino Acid Disorders 105
    AMINO ACID DISORDERS 105 Massaro, A. S. (1995). Trypanosomiasis. In Guide to Clinical tions in biological fluids relatively easy. These Neurology (J. P. Mohrand and J. C. Gautier, Eds.), pp. 663– analyzers separate amino acids either by ion-ex- 667. Churchill Livingstone, New York. Nussenzweig, V., Sonntag, R., Biancalana, A., et al. (1953). Ac¸a˜o change chromatography or by high-pressure liquid de corantes tri-fenil-metaˆnicos sobre o Trypanosoma cruzi in chromatography. The results are plotted as a graph vitro: Emprego da violeta de genciana na profilaxia da (Fig. 1). The concentration of each amino acid can transmissa˜o da mole´stia de chagas por transfusa˜o de sangue. then be calculated from the size of the corresponding O Hospital (Rio de Janeiro) 44, 731–744. peak on the graph. Pagano, M. A., Segura, M. J., DiLorenzo, G. A., et al. (1999). Cerebral tumor-like American trypanosomiasis in Most amino acid disorders can be diagnosed by acquired immunodeficiency syndrome. Ann. Neurol. 45, measuring the concentrations of amino acids in 403–406. blood plasma; however, some disorders of amino Rassi, A., Trancesi, J., and Tranchesi, B. (1982). Doenc¸ade acid transport are more easily recognized through the Chagas. In Doenc¸as Infecciosas e Parasita´rias (R. Veroesi, Ed.), analysis of urine amino acids. Therefore, screening 7th ed., pp. 674–712. Guanabara Koogan, Sa˜o Paulo, Brazil. Spina-Franc¸a, A., and Mattosinho-Franc¸a, L. C. (1988). for amino acid disorders is best done using both South American trypanosomiasis (Chagas’ disease). In blood and urine specimens. Occasionally, analysis of Handbook of Clinical Neurology (P.
    [Show full text]
  • Blueprint Genetics Primary Hyperoxaluria Panel
    Primary Hyperoxaluria Panel Test code: KI0801 Is a 3 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of hyperoxaluria. About Primary Hyperoxaluria The primary hyperoxalurias are rare disorders of glyoxylate metabolism, which result in markedly increased endogenous oxalate synthesis by the liver. They are characterized by an excess of oxalate resulting in manifestations ranging from occasional renal stones, recurrent nephrolithiasis and nephrocalcinosis to end-stage renal disease (ESRD) and systemic oxalosis. Presenting ranges from the neonatal period to adulthood. Among disorders causing hyperoxaluria, the primary hyperoxalurias are the most severe, ultimately leading to ESRD and if untreated, death in most patients. Type I primary hyperoxaluria (PH1), is caused by deficient or absent activity of liver-specific peroxisomal alanine glyoxylate aminotransferase (AGT). In some patients with PH1 type disease, the enzyme is present but mistargeted to mitochondria where it is metabolically inactive. The severe infantile form is characterized by a failure to thrive, nephrocalcinosis with or without nephrolithiasis and early ESRD. Onset in childhood and adolescence is often characterized by recurrent urolithiasis (with or without nephrocalcinosis) and progressive renal failure. The late onset form is characterized by occasional renal stones with onset in adulthood, but acute renal failure caused by bilateral obstruction of the kidneys by oxalate stones may occur. Other manifestations include urinary tract infections, dysuria and hematuria. The ongoing systemic oxalosis also may lead to other clinical manifestations such as cardiac conduction defects, vascular calcification with distal gangrene, disturbed vision, specific brown colored retinal deposits, skin nodules, joint involvement and bone disease leading to fractures in long-term dialysis-dependent patients.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,981,835 Austin-Phillips Et Al
    USOO598.1835A United States Patent (19) 11 Patent Number: 5,981,835 Austin-Phillips et al. (45) Date of Patent: Nov. 9, 1999 54) TRANSGENIC PLANTS AS AN Brown and Atanassov (1985), Role of genetic background in ALTERNATIVE SOURCE OF Somatic embryogenesis in Medicago. Plant Cell Tissue LIGNOCELLULOSC-DEGRADING Organ Culture 4:107-114. ENZYMES Carrer et al. (1993), Kanamycin resistance as a Selectable marker for plastid transformation in tobacco. Mol. Gen. 75 Inventors: Sandra Austin-Phillips; Richard R. Genet. 241:49-56. Burgess, both of Madison; Thomas L. Castillo et al. (1994), Rapid production of fertile transgenic German, Hollandale; Thomas plants of Rye. Bio/Technology 12:1366–1371. Ziegelhoffer, Madison, all of Wis. Comai et al. (1990), Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS 73 Assignee: Wisconsin Alumni Research elements. Plant Mol. Biol. 15:373-381. Foundation, Madison, Wis. Coughlan, M.P. (1988), Staining Techniques for the Detec tion of the Individual Components of Cellulolytic Enzyme 21 Appl. No.: 08/883,495 Systems. Methods in Enzymology 160:135-144. de Castro Silva Filho et al. (1996), Mitochondrial and 22 Filed: Jun. 26, 1997 chloroplast targeting Sequences in tandem modify protein import specificity in plant organelles. Plant Mol. Biol. Related U.S. Application Data 30:769-78O. 60 Provisional application No. 60/028,718, Oct. 17, 1996. Divne et al. (1994), The three-dimensional crystal structure 51 Int. Cl. ............................. C12N 15/82; C12N 5/04; of the catalytic core of cellobiohydrolase I from Tricho AO1H 5/00 derma reesei. Science 265:524-528.
    [Show full text]
  • Synthesis and Structural Characterization of Glucooligosaccharides and Dextran from Weissella Confusa Dextransucrases
    YEB Recent Publications in this Series Dextran from and and Structural Characterization of Glucooligosaccharides QIAO SHI Synthesis 4/2016 Hany S.M. EL Sayed Bashandy Flavonoid Metabolomics in Gerbera hybrida and Elucidation of Complexity in the Flavonoid Biosynthetic Pathway 5/2016 Erja Koivunen Home-Grown Grain Legumes in Poultry Diets 6/2016 Paul Mathijssen DISSERTATIONES SCHOLA DOCTORALIS SCIENTIAE CIRCUMIECTALIS, Holocene Carbon Dynamics and Atmospheric Radiative Forcing of Different Types of Peatlands ALIMENTARIAE, BIOLOGICAE. UNIVERSITATIS HELSINKIENSIS 21/2016 in Finland 7/2016 Seyed Abdollah Mousavi Revised Taxonomy of the Family Rhizobiaceae, and Phylogeny of Mesorhizobia Nodulating Glycyrrhiza spp. 8/2016 Sedeer El-Showk Auxin and Cytokinin Interactions Regulate Primary Vascular Patterning During Root QIAO SHI Development in Arabidopsis thaliana 9/2016 Satu Olkkola Antimicrobial Resistance and Its Mechanisms among Campylobacter coli and Campylobacter Synthesis and Structural Characterization of upsaliensis with a Special Focus on Streptomycin 10/2016 Windi Indra Muziasari Glucooligosaccharides and Dextran from Impact of Fish Farming on Antibiotic Resistome and Mobile Elements in Baltic Sea Sediment Weissella confusa Dextransucrases 11/2016 Kari Kylä-Nikkilä Genetic Engineering of Lactic Acid Bacteria to Produce Optically Pure Lactic Acid and to Develop a Novel Cell Immobilization Method Suitable for Industrial Fermentations 12/2016 Jane Etegeneng Besong epse Ndika Molecular Insights into a Putative Potyvirus RNA Encapsidation
    [Show full text]
  • Inherited Metabolic Disorders)
    1 โรคพันธุกรรมเมตาบอลิก (inherited metabolic disorders) บทนํา โรคพันธุกรรมเมตาบอลิคนั้น มีผู้ประเมินไว้ว่ามีหลายร้อยโรคด้วยกัน และเป็นที่ยอมรับว่า อุบัติการของโรคกลุ่มนี้มักจะน้อยกว่าความเป็นจริง เนื่องจากการวินิจฉัยโรคทําได้ด้วยความ ยากลําบาก แพทย์ทั่วไปมักรู้จักค่อนข้างน้อย หรือให้การวินิจฉัยไม่ถูกต้อง ด้วยเหตุผลหลาย ประการ 1). การวินิจฉัยทําได้ค่อนข้างยาก เนื่องจากแต่ละโรคพบได้น้อยคือ จัดเป็น rare disease ทําให้แพทย์ไม่ค่อยนึกถึงเมื่อพบผู้ป่วย จนอาการค่อนข้างมาก หรือเมื่อได้แยกโรคที่พบได้บ่อย ออกไปแล้ว 2). การตรวจทางห้องปฎิบัติการโดยเฉพาะการตรวจเลือดและปัสสาวะเบื้องต้น มักไม่ ค่อยบอกโรคชัดเจน ยกเว้นส่งตรวจพิเศษบางอย่างเช่นการวิเคราะห์ plasma amino acid หรือ urine organic acid 3). ในทารกแรกเกิดซึ่งมีโอกาสพบโรคกลุ่มนี้ได้บ่อย มักจะมีการตอบสนองต่อ severe overwhelming illness อย่างมีขีดจํากัด หรือแสดงอาการอย่าง nonspecific เช่น poor feeding,lethargy เป็นต้น 4).กุมารแพทย์คิดถึงโรคกลุ่มนี้ในบางภาวะเท่านั้นเช่นภาวะปัญญาอ่อน หรือชักที่คุมได้ยากและมองข้ามอาการแสดงบางอย่างที่อาจเป็นเงื่อนงําสําคัญในการวินิจฉัยโรค โรคพันธุกรรมเมตาบอลิก ที่เรียกว่า inherited metabolic disorders หรือ inborn errors of metabolism (IBEM) เป็นโรคพันธุกรรมกลุ่มหนึ่งที่เกิดจากความผิดปกติของยีนเดี่ยว ที่มีความ ผิดปกติของการเรียงลําดับของเบสหรือสายDNA ก่อให้เกิดความผิดปกติของ enzymes, receptors, transport proteins, structural proteins, หรือส่วนประกอบอื่นของเซลล์แล้วส่งผลให้ เกิดความผิดปกติของขบวนการย่อยสลาย (catabolism) หรือขบวนการสังเคราะห์ (anabolism) สารอาหาร การเปลี่ยนแปลงที่ระดับ DNA ของโรคกลุ่มนี้อาจเกิดจากการกลายพันธุ์ของยีนที่สร้าง enzyme หรือยีนที่สร้างสารควบคุมหรือส่งเสริมการทํางานของ
    [Show full text]